PBMs Eye Acquisitions In “Target-Rich Environment”
This article was originally published in The Pink Sheet Daily
Executive Summary
Medco could limit cost of an acquisition to $300 mil. as the pharmacy benefit manager plans to have cash on hand to build its Medicare Rx business. Express Scripts says it is interested in acquisitions that would add scale to its PBM and specialty pharmacy businesses.
You may also be interested in...
Express Scripts Anticipates Growth In 2005 From Zithromax, Zofran Generics
PBM cites anticipated contribution to growth from several first-time generics that could enter the market in 2005. Nevertheless, Express Scripts concedes that generic utilization growth will be weaker in 2005 than in other years. Subsidiary CuraScript will aid PBM's growth by converting clients that use an outside specialty pharmacy provider.
Medco Warms Up To Part D: Plans "Creative" Role In Medicare Rx
The PBM is now "hopeful" that it can participate in the stand-alone Medicare drug insurance market after previously focusing on the "fallback" opportunity. Medco is working on a "creative and innovative solution" that will resolve its concerns about going at risk.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.